ストックスクリーナーアプリを入手
10.25
0.58%
-0.06
プレマーケット:
10.49
0.24
+2.34%
Adma Biologics Inc (ADMA) 最新ニュース
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth? - Yahoo Finance
CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Weighing ADMA Biologics (ADMA) After A 56% One-Year Share Price Decline - Yahoo Finance
Assessing ADMA Biologics (ADMA) Valuation As Securities Investigations Follow Channel Stuffing Allegations - Yahoo Finance
ADMA Secures FDA Approval for Asceniv Expansion - GuruFocus
ADMA Biologics’ ASCENIV Receives FDA Approval to Treat Pediatric Immunodeficiency Patients Aged 2 and Older - Minichart
ADMA Biologics Receives FDA Approval to Expand Asceniv Label for Pediatric Patients - Moomoo
ADMA Biologics Gains FDA Approval for Expanded ASCENIV Label - TipRanks
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older - The Manila Times
Children as young as 2 gain access to ADMA's ASCENIV after FDA approval - Stock Titan
[8-K] ADMA BIOLOGICS, INC. Reports Material Event - Stock Titan
ADMA Biologics Announces FDA Approval to Expand the Label - GlobeNewswire
$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% - GlobeNewswire
BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - GlobeNewswire Inc.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are ... - Caledonian Record
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
A Look At ADMA Biologics (ADMA) Valuation After Short Seller Report And Legal Investigation - Sahm
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - PR Newswire
MSN Money - MSN
Earnings Preview: ADMA to Report Financial Results Post-market on May 06 - Moomoo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ... - Caledonian Record
ADMA stock downgraded by Cantor as ‘channel stuffing’ claims shake investor confidence - MSN
Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vanguard (NASDAQ: ADMA) reports 12.11M shares, 5.08% stake - Stock Titan
Short seller report alleges ADMA Biologics financial misrepresentation - MSN
Immunoglobulin Market Leading Players AnalysisADMA - openPR.com
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026 - Moomoo
Investigation into ADMA Biologics for Potential Securities Fraud - Intellectia AI
ADMA Biologics (NASDAQ:ADMA) Stock Rating Lowered by Zacks Research - MarketBeat
ADMA Biologics (ADMA) Projected to Post Earnings on Wednesday - MarketBeat
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA ... - Caledonian Record
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - Yahoo Finance
ADMA Biologics Investor News: If You Have Suffered Losses - GlobeNewswire
ADMA Biologics rejects claims made in short-seller report - MSN
ADMA Biologics drops amid short report from Culper Research - MSN
ADMA Biologics extends selloff as Cantor downgrades after short report - MSN
ADMA Biologics says short report contains misleading, inaccurate statements - MSN
Q2 2025 ADMA Biologics Inc Earnings Call Transcript - GuruFocus
ADMA Biologics Inc (ADMA) Stock Analysis: Could an 83% Potential Upside Be Within Reach? - DirectorsTalk Interviews
Calamos Advisors LLC Increases Stock Position in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics gains after refuting short seller claims - MSN
Canaccord’s Support and Short-Seller Rebuttal Could Be A Game Changer For ADMA Biologics (ADMA) - Yahoo Finance
Does ADMA Biologics' growth story outweigh short-seller concerns? - MSN
ADMA stock drops 6% after Culper Research alleges channel stuffing - MSN
Down 27% in 4 weeks, here's why Adma Biologics (ADMA) looks ripe for a turnaround - MSN
Wall Street Zen Upgrades ADMA Biologics (NASDAQ:ADMA) to Buy - MarketBeat
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inqu - GuruFocus
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):